Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-12-24, Stock:ABBV, The news for the past five days is as follows:
2018-12-17: NEWS1: AbbVie (ABBV) Stock Moves -0.79%: What You Should Know.NEWS2: AbbVie Announces Executive Leadership Changes.NEWS3: Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial.
2018-12-18: NEWS1: The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney.NEWS2: The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney.NEWS3: Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study.NEWS4: Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study.NEWS5: Pfizer: Recent Developments and Analysts’ Recommendations.NEWS6: Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study.NEWS7: The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney.NEWS8: AbbVie (ABBV) Stock Moves -0.79%: What You Should Know.NEWS9: AbbVie (ABBV) Stock Moves -0.79%: What You Should Know.
2018-12-19: NEWS1: This High-Yield Dividend Stock Could Outperform If the Stock Market Rallies.NEWS2: Why Eli Lilly Stock Is Still Shining in the Darkness.NEWS3: Today's Research Reports on Trending Tickers: Dr. Reddy's Laboratories and AbbVie.
2018-12-20: NEWS1: Gilead Partners with Scholar Rock for Fibrotic Disease Drugs.NEWS2: AbbVie Rises 3%.NEWS3: Notable ETF Inflow Detected - XLV, ABBV, ABT, CVS.NEWS4: Notable ETF Inflow Detected - XLV, ABBV, ABT, CVS.NEWS5: AbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis.NEWS6: AbbVie to Present at the 37th Annual J.P. Morgan Healthcare Conference.NEWS7: 3 Top Healthcare Stocks to Buy in December.
2018-12-21: NEWS1: AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib.NEWS2: AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib.NEWS3: Noteworthy Friday Option Activity: CLVS, ABBV, AAL.NEWS4: Noteworthy Friday Option Activity: CLVS, ABBV, AAL.NEWS5: AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib.NEWS6: Gilead Partners with Scholar Rock for Fibrotic Disease Drugs.NEWS7: Gilead Partners with Scholar Rock for Fibrotic Disease Drugs.

Answer: Decrease